Agilent Technologies, Inc. (NYSE:A – Get Rating) was the recipient of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 2,880,000 shares, a decrease of 18.9% from the May 15th total of 3,550,000 shares. Approximately 1.0% of the company’s stock are sold short. Based on an average daily volume of 1,970,000 shares, the short-interest ratio is currently 1.5 days.
In related news, VP Jacob Thaysen sold 5,879 shares of the company’s stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $127.43, for a total value of $749,160.97. Following the completion of the sale, the vice president now directly owns 88,737 shares in the company, valued at $11,307,755.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
A number of institutional investors have recently modified their holdings of the business. Offit Capital Advisors LLC raised its holdings in shares of Agilent Technologies by 9.9% in the first quarter. Offit Capital Advisors LLC now owns 2,486 shares of the medical research company’s stock valued at $329,000 after buying an additional 223 shares during the last quarter. Paragon Private Wealth Management LLC boosted its position in Agilent Technologies by 5.0% in the 1st quarter. Paragon Private Wealth Management LLC now owns 12,781 shares of the medical research company’s stock valued at $1,631,000 after buying an additional 606 shares during the last quarter. J.W. Cole Advisors Inc. boosted its position in Agilent Technologies by 7,201.6% in the 1st quarter. J.W. Cole Advisors Inc. now owns 124,493 shares of the medical research company’s stock valued at $45,000 after buying an additional 122,788 shares during the last quarter. American Trust boosted its position in Agilent Technologies by 195.7% in the 1st quarter. American Trust now owns 4,581 shares of the medical research company’s stock valued at $606,000 after buying an additional 3,032 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Agilent Technologies by 27.3% in the 1st quarter. Bank of America Corp DE now owns 2,397,727 shares of the medical research company’s stock valued at $317,291,000 after buying an additional 513,709 shares during the last quarter.
Agilent Technologies (NYSE:A – Get Rating) last posted its earnings results on Tuesday, May 24th. The medical research company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.12 by $0.01. The business had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.62 billion. Agilent Technologies had a return on equity of 27.42% and a net margin of 19.35%. Agilent Technologies’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company earned $0.97 EPS. Equities research analysts expect that Agilent Technologies will post 4.9 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 27th. Shareholders of record on Tuesday, July 5th will be paid a dividend of $0.21 per share. The ex-dividend date is Friday, July 1st. This represents a $0.84 annualized dividend and a yield of 0.75%. Agilent Technologies’s dividend payout ratio is 20.24%.
A number of research firms have issued reports on A. Robert W. Baird raised their target price on Agilent Technologies from $155.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, May 25th. Truist Financial cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, April 19th. Stifel Nicolaus dropped their price objective on shares of Agilent Technologies from $169.00 to $145.00 and set a “hold” rating on the stock in a report on Wednesday, February 23rd. Citigroup dropped their price objective on shares of Agilent Technologies from $190.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, February 23rd. Finally, KeyCorp dropped their price objective on shares of Agilent Technologies from $195.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, June 2nd. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $159.91.
About Agilent Technologies (Get Rating)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- The Analysts Upgrade… Retail Stocks?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.